Working… Menu

Proximal Femoral Nail Antirotation™ (PFNA) Versus Gamma Nail 3™ (Gamma3) for Intramedullary Nailing of Unstable Trochanteric Fractures (PROGAINT-ES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00736684
Recruitment Status : Completed
First Posted : August 18, 2008
Last Update Posted : February 11, 2011
Synthes Inc.
Information provided by:
AO Innovation Translation Center

Brief Summary:
The purpose of this study is to compare rates of any fracture fixation complication and revision rates after intramedullary fixation of unstable trochanteric fractures between the Proximal Femoral Nail Antirotation™ (PFNA)(Investigational Group) and Gamma Nail 3™ (Gamma3) (Control Group).

Condition or disease Intervention/treatment Phase
Unstable Trochanteric Fractures Device: Proximal Femoral Nail AntirotationTM (PFNA) Device: Gamma Nail 3TM (Gamma3) Phase 4

Detailed Description:
Intramedullary nailing of unstable per- and subtrochanteric femoral fractures is a standard procedure in trauma and orthopaedic surgery. Unstable fractures treated with intramedullary nailing carry the risk of fracture fixation complications. The PFNA (Synthes) has evolved from the original PFN design, featuring a novel antirotation screw. Apart from the prevention of excess rotational forces, this supporting element may enhance the overall stability of the construct, thus potentially reducing fracture fixation complications. Empirical information about the fracture fixation complication rates of the PFNA device is not available. The primary objective of this study is to compare the 1-year fracture fixation rates between the PFNA and Gamma Nail 3™ (Stryker). Secondary objectives of the study are to compare differences in functional outcomes, quality of life outcomes, safety, radiological outcomes, handling and perceived effectiveness between the devices.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 440 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Proximal Femoral Nail Antirotation™ (PFNA) Versus Gamma Nail 3™ (Gamma3) for Intramedullary Nailing of Unstable Trochanteric Fractures - a Multicenter Randomized Controlled Trial
Study Start Date : November 2007
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fractures

Arm Intervention/treatment
Active Comparator: 1
Proximal Femoral Nail AntirotationTM (PFNA)
Device: Proximal Femoral Nail AntirotationTM (PFNA)
intramedullary nailing

Gamma Nail 3TM (Gamma3)
Device: Gamma Nail 3TM (Gamma3)
intramedullary nailing

Primary Outcome Measures :
  1. Any fracture fixation complication. [ Time Frame: One year ]

Secondary Outcome Measures :
  1. Bone union/fusion as evaluated by CT-scanning, health-related quality of life, disease-specific functional scoring, activities of daily living, mortality, radiological parameters, surgery details and surgeons' evaluation of handling and effectiveness. [ Time Frame: One year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 55 years and more
  • Patients with isolated, unstable, closed or type 1 open trochanteric fractures, classified as AO 31-A2 or AO 31-A3
  • Definitive primary fracture treatment with PFNA or Gamma3 (defined inTable 1) within three days after the index event
  • Signed written informed consent (by the subjects or legal guardian) and agreement to attend the planned follow-ups

Exclusion Criteria:

  • Pathologic fracture of any other cause than osteoporosis
  • Patients or legal guardian refusing to sign the informed consent form
  • Multiple trauma
  • Type 2 and 3 open fractures
  • Drug or alcohol abuse
  • Wound and/or bone healing disorders of any other cause than diabetes mellitus or smoking
  • Active malignancy
  • Expected life expectancy ≤ 3 months
  • Inability to walk independently prior to injury event (use of one stick is allowed. Not meeting inclusion criteria are bedridden, wheel-chair ridden and walker dependent subjects)
  • Neurological and psychiatric disorders that would preclude reliable assessment (eg,, Parkinson disease, Multiple sclerosis, severe depression)
  • Rheumatoid arthritis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00736684

Layout table for location information
Hospital Universitario "Marqués de Valdecilla"
Santander, Cantabria, Spain, 39008
Hospital Clinic
Barcelona, Cataluña, Spain, 08036
Hospital Gregorio Marañon
Madrid, Spain, 28007
Hospital Puerta de Hierro
Madrid, Spain, 28035
H.U. Virgen de la Arrixaca
Murcia, Spain, 30071
Hospital Donostia
San Sebastián, Spain, 20014
Sponsors and Collaborators
AO Clinical Investigation and Documentation
Synthes Inc.
Layout table for investigator information
Study Director: Beate P. Hanson, MD AO Clinical Investigation and Documentation, Davos, Switzerland
Principal Investigator: Javier Vaquero Martin, MD Hospital Gregorio Marañon, Madrid, Spain
Layout table for additonal information
Responsible Party: Javier Vaquero Martin, MD, Hospital Gregorio Marañon Identifier: NCT00736684    
Other Study ID Numbers: PROGAINT-ES-08
First Posted: August 18, 2008    Key Record Dates
Last Update Posted: February 11, 2011
Last Verified: February 2011
Keywords provided by AO Innovation Translation Center:
Femoral fractures [MeSH]
hip fractures [MeSH]
trochanteric fractures (femoral neck fractures [MeSH])
intramedullary nailing (fracture fixation, intramedullary [MeSH])
complex femoral fractures
femoral nail
surgical treatment (surgical procedures, operative [MeSH])
Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Bone
Hip Fractures
Wounds and Injuries
Femoral Fractures
Hip Injuries
Leg Injuries